Literature DB >> 9356041

The effect of HLA-B allele on the IDDM risk defined by DRB1*04 subtypes and DQB1*0302.

S Nejentsev1, H Reijonen, B Adojaan, L Kovalchuk, A Sochnevs, E I Schwartz, H K Akerblom, J Ilonen.   

Abstract

The genes encoding the HLA-DQ heterodimer molecules, DQB1 and DQA1, have been found to have the strongest association with IDDM risk, although there is cumulative evidence for the effect of other gene loci within the major histocompatibility complex gene region. After the HLA-DQ locus, the HLA-DR locus has been suggested most often as contributing to the disease susceptibility. In this study we analyzed at the population level the effect of DR4 subtypes and class I, HLA-B alleles, on IDDM risk when the influence of the DQ locus was stratified. In all three populations studied (Estonian, Latvian, and Russian), DQB1*0302 haplotypes most frequently carried DRB1*0401 or DRB1*0404. DRB1*0401 was the most prevalent subtype in IDDM patients, whereas DRB1*0404 was decreased in frequency. DRB1*0402 was also prevalent among Russian haplotypes, but was not associated with IDDM risk. When HLA-B alleles were analyzed, strong associations between the presence of specific B alleles and DRB1*04 subtypes were detected. The HLA-B39 allele was found significantly more often in DRB1*0404-DQB1*0302-positive patients than in healthy control subjects positive for this haplotype: 27 of 54 (50%) vs. 4 of 49 (8.2%) (P < 0.0001). The results demonstrate that DQ and DR genes cannot explain all of the HLA-linked susceptibility to IDDM, and that the existence of a susceptibility locus telomeric to DR is probable.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9356041     DOI: 10.2337/diab.46.11.1888

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  16 in total

Review 1.  Genetic predisposition to IDDM.

Authors:  S Caillat-Zucman; J F Bach
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 2.  Molecular aspects of type 1 diabetes.

Authors:  M A Kelly; M L Rayner; C H Mijovic; A H Barnett
Journal:  Mol Pathol       Date:  2003-02

Review 3.  Genetic susceptibility in type 1 diabetes and its associated autoimmune disorders.

Authors:  Akane Ide; George S Eisenbarth
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

Review 4.  Effector lymphocytes in islet cell autoimmunity.

Authors:  Pere Santamaria
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

Review 5.  Genetics of type 1 diabetes.

Authors:  Janelle A Noble; Henry A Erlich
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 6.  Use of nonobese diabetic mice to understand human type 1 diabetes.

Authors:  Terri C Thayer; S Brian Wilson; Clayton E Mathews
Journal:  Endocrinol Metab Clin North Am       Date:  2010-07-08       Impact factor: 4.741

7.  Beyond HLA-A*0201: new HLA-transgenic nonobese diabetic mouse models of type 1 diabetes identify the insulin C-peptide as a rich source of CD8+ T cell epitopes.

Authors:  Zoltan Antal; Jason C Baker; Carla Smith; Irene Jarchum; Jeffrey Babad; Gayatri Mukherjee; Yang Yang; John Sidney; Alessandro Sette; Pere Santamaria; Teresa P DiLorenzo
Journal:  J Immunol       Date:  2012-04-25       Impact factor: 5.422

8.  Identification of novel IGRP epitopes targeted in type 1 diabetes patients.

Authors:  Irene Jarchum; Lynn Nichol; Massimo Trucco; Pere Santamaria; Teresa P DiLorenzo
Journal:  Clin Immunol       Date:  2008-03-20       Impact factor: 3.969

9.  The role of HLA class I gene variation in autoimmune diabetes.

Authors:  Charles Sia; Michael Weinem
Journal:  Rev Diabet Stud       Date:  2005-08-10

10.  Predominant occupation of the class I MHC molecule H-2Kwm7 with a single self-peptide suggests a mechanism for its diabetes-protective effect.

Authors:  Daniel R Brims; Jie Qian; Irene Jarchum; Leann Mikesh; Edith Palmieri; Udupi A Ramagopal; Vladimir N Malashkevich; Rodolfo J Chaparro; Torben Lund; Masakazu Hattori; Jeffrey Shabanowitz; Donald F Hunt; Stanley G Nathenson; Steven C Almo; Teresa P Dilorenzo
Journal:  Int Immunol       Date:  2010-01-21       Impact factor: 4.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.